Posts filed under: Finance

Melbourne, Australia, and San Francisco, USA, Sept. 19th, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased to announce the conclusion of a collaboration and licensing agreement with CellSight Technologies, Inc....
Continue Reading →
Melbourne, Australia, Sept. 18, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased to announce that Mr. Kevin McCann AM and Dr. Mark Nelson have been appointed to the Board of...
Continue Reading →
Melbourne, Australia, July 31, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased to announce the completion of a Master Services Agreement (“MSA”) with Cyclotek (Aust) Pty Ltd (“Cyclotek”). Under the...
Continue Reading →
Melbourne, Australia and Cambridge, UK, July. 18, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased to announce a licence agreement collaboration with Abzena plc (“Abzena”) for its prostate-specific membrane antigen...
Continue Reading →
Melbourne, Australia and Dresden, Germany, Jan. 18, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased to announce a product development partnership with Therapeia GmbH & Co KG (“Therapeia”). Telix will...
Continue Reading →
Melbourne, Australia and Nantes, France, Jan. 18, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased to announce the completion of a product collaboration and purchase option agreement with Atlab Pharma...
Continue Reading →
Telix receives exclusive worldwide rights for the development and commercialization of diagnostic agent REDECTANE® (INN: 124I-Girentuximab) Telix also receives development rights to Girentuximab for use with therapeutic radionuclides, such as...
Continue Reading →